The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication

NCT04800692 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Claudication, Intermittent
Peripheral Artery Disease
Peripheral Vascular Diseases

Interventions

DRUG: Tetrahydrobiopterin 10 mg/kg
DRUG: Tetrahydrobiopterin 20 mg/kg
DRUG: L-Ascorbate
DRUG: L-Arginine

Sponsor

Louis Messina

Collaborators

[object Object]